This Amyloid Transthyretin (ATTR) Learning Center is developed by key opinion leaders in the fields of cardiology and neurology to educate healthcare providers on ATTR, a progressive, multisystemic disease that is often misdiagnosed due to a lack of familiarity with its clinical manifestations. Explore the latest advancements, mechanisms of action, and clinical applications of multiple therapies designed to care for patients with ATTR. Our mission is to turbocharge healthcare providers’ clinical proficiency, empowering them to skillfully navigate the nuances of ATTR within a comprehensive educational environment. Prepare to elevate your understanding of ATTR and impact patient care – because the future of ATTR education starts here.
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
Remarkable results in phase 3 study with vutrisiran in patients with ATTR-CM
Remarkable results in phase 3 study with vutrisiran in patients with ATTR-CM
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy
Beyond the Horizon: HELIOS Clinical Trials in ATTR Cardiomyopathy
Treating ATTR-CM With a Novel Therapeutic Approach: Understanding the ATTRibutes to Success
Treating ATTR-CM With a Novel Therapeutic Approach: Understanding the ATTRibutes to Success
Transformation of Treatment Strategies for ATTR Amyloidosis
Transformation of Treatment Strategies for ATTR Amyloidosis
